Connect Biopharma has reported 52-week improvements across multiple endpoints in a phase 3 trial of its eczema drug candidate, fueling the biotech’s belief that its molecule is ...

Approval in moderate-to-severe patients was based on pivotal trial results showing over four times more Dupixent patients experienced sustained ...

Sanofi and Regeneron’s Dupixent approved in Japan as the first targeted medicine to treat adults with bullous pemphigoidApproval in ...

The Ministry of Health, Labor and Welfare in Japan has granted marketing and manufacturing authorization for Dupixent ...

Approval in moderate-to-severe patients was based on pivotal trial results showing over four times more Dupixent patients experienced sustained disease remission through Week 36 compared with placebo ...

Presentations at the 2026 meeting of the American Academy of Dermatology not only demonstrate the therapeutic potential of ...

Despite hitting key goals across three late-stage studies, the drug, which targets the “OX40” ligand, raises safety and ...

Sanofi has signed an exclusive global licence agreement with Kali Therapeutics for KT501, a new tri-specific antibody for B ...

Sandoz has struck a deal with Samsung Bioepis to partner on up to five biosimilars, with the first being SB36, a copycat of Takeda’s Entyvio (vedolizumab), which is being developed by the South ...

Pharma stocks draw interest as pipelines, clinical trials and acquisitions support growth outlook despite patent expiry ...

Friday, March 27, 2026 The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily ...